An­ti­body leg­end Till­man Gern­gross in­tro­duces his lat­est com­pa­ny, with an In­novent deal al­ready lined up

When Har­vard Med­ical School pro­fes­sor Leonard Zon told Dart­mouth pro­fes­sor and se­r­i­al en­tre­pre­neur Till­man Gern­gross he had a ques­tion, Gern­gross jok­ing­ly replied: “The an­swer is an­ti­bod­ies. What’s the ques­tion?”

Zon had been talk­ing with his daugh­ter about a pa­tient who died of pan­cre­ati­tis dur­ing her res­i­den­cy. Soon, Gern­gross and Zon be­gan brain­storm­ing how they could use an­ti­bod­ies to in­hib­it dys­reg­u­lat­ed pro­teas­es and oth­er en­zymes to treat in­flam­ma­to­ry dis­eases like pan­cre­ati­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER